HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Idarubicin (4 Demethoxydaunorubicin)

An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Also Known As:

4 Demethoxydaunorubicin; 4-Desmethoxydaunorubicin; IMI-30; Idarubicin Hydrochloride; NSC-256439; 4 Desmethoxydaunorubicin; Hydrochloride, Idarubicin; IMI 30; IMI30; NSC 256439; NSC256439; 4-Demethoxydaunorubicin; 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-

Networked: 692 relevant articles (79 outcomes, 229 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Garcia-Manero, Guillermo: 12 articles (05/2015 - 08/2002)
2.	Faderl, Stefan: 10 articles (11/2013 - 08/2002)
3.	Kantarjian, Hagop: 9 articles (05/2015 - 01/2003)
4.	O'Brien, Susan: 8 articles (05/2015 - 08/2002)
5.	Ravandi, Farhad: 8 articles (05/2015 - 02/2007)
6.	Cortes, Jorge: 8 articles (05/2015 - 08/2002)
7.	Giles, Francis J: 7 articles (02/2013 - 06/2002)
8.	Kantarjian, Hagop M: 7 articles (06/2012 - 06/2002)
9.	Estey, Elihu H: 6 articles (06/2015 - 06/2002)
10.	Cortes, Jorge E: 6 articles (06/2012 - 06/2002)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2014 - "Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial." 01/01/2004 - "This study has been carried out in our clinic in order to evaluate the efficiency of the acute nonlymphoblastic leukemia protocol which includes idarubicin. " 10/01/1999 - "A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients." 09/01/2014 - "A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. " 10/01/2013 - "The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia."
2.	Leukemia 05/01/1988 - "2 out of the 11 anthracycline pretreated patients (91-880 mg/m2) with acute leukemia reached a complete remission undergoing idarubicin p.o. " 04/30/1986 - "This study confirms that idarubicin is effective in acute leukemia also by oral route. " 09/01/2006 - "In this study, 155 leukemia patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin. " 09/01/2006 - "To evaluate the safety of domestically produced idarubicin in the treatment of acute leukemia by a multicenter randomized control trial. " 09/01/2006 - "[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]."
3.	Acute Promyelocytic Leukemia 11/01/2002 - "Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up." 05/05/2011 - "From July 1993 to May 2000, 807 genetically proven newly diagnosed acute promyelocytic leukemia patients received ATRA plus idarubicin as induction, followed by 3 intensive consolidation courses. " 10/28/2010 - "After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving all-trans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. " 04/01/1990 - "Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA." 09/01/2007 - "Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?"
4.	Breast Neoplasms (Breast Cancer) 05/01/2006 - "This study shows that idarubicin at the dose of 5 mg/day for 21 consecutive days is feasible and effective in elderly breast cancer patients but do not demonstrate an improvement in efficacy. " 02/01/1991 - "Idarubicin is a new anthracycline derivative with therapeutic efficacy in metastatic breast cancer. " 05/01/2006 - "To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. " 05/01/2006 - "Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring." 06/01/2000 - "Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients."
5.	Neoplasms (Cancer) 01/01/2008 - "Idarubicin is a clinically effective synthetic anthracycline analog used in the treatment of several human neoplasms. " 02/01/2015 - "Histopathologic and clinical studies are needed to evaluate idarubicin release around the DEE agents in tumor tissue and to confirm safety and efficacy." 08/01/1990 - "Twenty-one adult patients with refractory solid tumors were treated on a phase I study of idarubicin (4-demethoxydaunorubicin) administered daily for 3 days every 3 weeks. " 01/01/1988 - "In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. " 01/01/1988 - "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer."

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	Daunorubicin (Cerubidine)
3.	Etoposide (VP 16)
4.	Doxorubicin (Adriamycin)
5.	Mitoxantrone (Novantrone)
6.	Tretinoin (Retinoic Acid)
7.	Anthracyclines
8.	Prednisone (Sone)
9.	Cyclophosphamide (Cytoxan)
10.	Vincristine (Oncovin)

Related Therapies and Procedures

1.	Remission Induction
2.	Drug Therapy (Chemotherapy)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Stem Cell Transplantation
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)